Health Care · Pharmaceutical Preparations

TVRD Tvardi Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1346830104 filings
Russell 2000

TVRD at a glance

Tvardi Therapeutics, Inc. (TVRD, SEC CIK 1346830) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53.
  • As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Tvardi Therapeutics, Inc. (TVRD) shares worth $2.0 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2024
$7.1M
−66.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
16 funds
$2.0M · +3 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes identified from the March 31, 2026 Form 10-K
  • Clinical-stage business risk: adverse events could impair financial condition, results, and growth prospects
  • Market risk: adverse developments could reduce the common stock price
  • Disclosure risk: unknown or currently immaterial risks could impair operations and stock value

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved or commercialized
  • Net loss $6.1M vs $5.5M YoY, operating expenses $6.3M vs $5.9M
  • Best program TTI-101 HCC spending $2.4M, up 307.0% YoY; TTI-109 spending $1.0M, down 49.0%
  • Cash $22.3M at September 30, 2026; operating cash use $21.5M for nine months
  • ATM proceeds $13.3M; substantial doubt about funding operations for at least one year, additional capital required

AI summary of the TVRD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease
  • FDA pre-IND feedback supports continued development of Tvardi’s next-generation oral STAT3 inhibitor

Item EX-99.1: Item EX-99.1

  • FDA pre-IND feedback supports Phase 2 development approach for TTI-109 in ulcerative colitis and Crohn’s disease
  • IND submission planned for 2027, with Phase 2 initiation contingent on FDA clearance and additional funding
Filed Nov 13, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 net loss $6.1M, or $(0.48) per share, versus $5.5M and $(0.59) year over year
  • R&D expense $4.5M, up from $3.6M, reflecting higher TTI-101 clinical costs

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026
  • Business highlights included alongside quarterly financial results
Filed Aug 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • TTI-109 healthy-volunteer data confirmed TTI-101-equivalent exposure, improved tolerability, and reductions in UC-relevant immune populations
  • UC selected as lead indication; U.S. addressable market approximately $3B versus $9B globally

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended June 30, 2026 results and business highlights announced August 14, 2026
  • Financial details and operating updates contained in Exhibit 99.1 press release

AI summaries of TVRD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TVRD

Don't miss the next TVRD filing

  • Alerts as it files. A push when TVRD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TVRD, by share count.
  • Ask anything. An AI agent that reads every TVRD filing and answers with sources.

TVRD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
HALL WALLACE L JRAJun 9, 2026-
Shah SujalAJun 9, 2026-
Smith CynthiaAJun 9, 2026-
WYZGA MICHAEL SAJun 9, 2026-
Shiff Susan Ph.D.AJun 9, 2026-
Alibhai Imran NizamudinAJan 29, 2026-
Conn Avi DanielAJan 29, 2026-
Kauh John Saewook M.D.AJan 29, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$21.0M$7.1M-
Operating Income-$121.5M-$58.4M-$26.7M
Net Income--$70.9M-$18.2M
Op. Margin-579.4%-818.0%-
Net Margin--993.0%-
Balance Sheet
Total Assets$125.8M$43.8M$32.1M
Equity--$4.6M$20.9M
ROE-1542.9%-87.0%
Per Share
EPS$-2.19$-15.53$-3.26
Cash Flow
Operating CF-$92.1M-$60.9M-$23.5M
CapEx$2.4M$1.0M-

Source: XBRL data in Tvardi Therapeutics, Inc. (TVRD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TVRD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TVRD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202616$2.0M
Q2 202613$1.3M
Q1 202616$3.7M
Q4 202516$5.6M
Q3 202515$43.2M
Q2 202512$18.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 88 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TVRD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
10-QNov 13, 2026Analysis
8-KNov 13, 2026Analysis-
8-KAug 14, 2026Analysis-
10-QAug 14, 2026Analysis
8-KJul 30, 2026Analysis-
8-KJul 17, 2026Analysis-
8-KJul 7, 2026Analysis-
4Jun 11, 2026--
8-KJun 11, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
10-QMay 8, 2026Analysis
8-KMay 8, 2026Analysis
10-KMar 31, 2026-
8-KMar 31, 2026--
8-KMar 6, 2026Analysis-
4Feb 2, 2026-
4Feb 2, 2026-
4Feb 2, 2026-
4Feb 2, 2026-
8-KJan 16, 2026-
4Dec 18, 2025-

Related Health Care companies

All Health Care →

TVRD SEC filings: frequently asked questions

Which institutions hold TVRD stock?

As of September 30, 2026, the largest Tvardi Therapeutics, Inc. (TVRD) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($430,000), Raymond James Financial ($348,000), Two Sigma Investments ($302,000), JPMorgan Chase & Co ($259,000), Renaissance Technologies LLC ($168,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TVRD's revenue in fiscal year 2024?

For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53. The figures come from the XBRL data in the 10-K.

What did TVRD report in its latest 8-K?

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease.

What are the latest TVRD SEC filings?

Tvardi Therapeutics, Inc. (TVRD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on June 11, 2026.

What is TVRD's SEC CIK number?

Tvardi Therapeutics, Inc. (TVRD)'s SEC Central Index Key (CIK) is 1346830. EDGAR lists every TVRD filing under that number.

Ask anything about TVRD

The research agent reads TVRD's filings, financials, insider trades and 13F holders, then answers with sources.